Cocrystal Pharma, Inc. - FORM 8-K - EX-10.12 - AMENDMENT NO. 1 TO LICENSE AGREEMENT - July 7, 2011

Attached files

file filename
8-K - FORM 8-K - Cocrystal Pharma, Inc.form8k.htm
EX-10.4 - FORM OF LLC MEMBERSHIP INTEREST PURCHASE AGREEMENT (BETAZONT LLC) - Cocrystal Pharma, Inc.exhibit10_4.htm
EX-10.1 - FORM OF LLC MEMBERSHIP INTEREST PURCHASE AGREEMENT (EQUALAN LLC) - Cocrystal Pharma, Inc.exhibit10_1.htm
EX-10.5 - FORM OF LOCKUP AGREEMENT - Cocrystal Pharma, Inc.exhibit10_5.htm
EX-10.3 - FORM OF LLC MEMBERSHIP INTEREST PURCHASE AGREEMENT (EQUACHEM LLC) - Cocrystal Pharma, Inc.exhibit10_3.htm
EX-10.2 - FORM OF STOCK PURCHASE AGREEMENT (BIOZONE LABORATORIES, INC.) - Cocrystal Pharma, Inc.exhibit10_2.htm
EX-10.7 - STOCK OPTION AGREEMENT BETWEEN DANIEL FISHER AND OPKO HEALTH, INC. - Cocrystal Pharma, Inc.exhibit10_7.htm
EX-10.8 - EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND BRIAN KELLER - Cocrystal Pharma, Inc.exhibit10_8.htm
EX-10.6 - STOCK OPTION AGREEMENT BETWEEN BRIAN KELLER AND OPKO HEALTH, INC. - Cocrystal Pharma, Inc.exhibit10_6.htm
EX-99.1 - PRESS RELEASE - Cocrystal Pharma, Inc.exhibit99_1.htm
EX-10.9 - EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND DANIEL FISHER - Cocrystal Pharma, Inc.exhibit10_9.htm
EX-10.11 - LICENSE AGREEMENT - Cocrystal Pharma, Inc.exhibit10_11.htm
EX-10.13 - AMENDMENT NO. 2 TO LICENSE AGREEMENT - Cocrystal Pharma, Inc.exhibit10_13.htm
EX-10.10 - EMPLOYMENT AGREEMENT BETWEEN THE COMPANY AND CHRISTIAN OERTLE - Cocrystal Pharma, Inc.exhibit10_10.htm
 
 
Exhibit 10.12
 
 
AMENDMENT TO LICENSE AGREEMENT
 
This Amendment ("Amendment'"). effective as of ________, 2011. modifies the terms of the License Agreement ("Agreement") between BioZone Laboratories. Inc. and BetaZone Laboratories LLC dated November 7. 2006.
 
Whereas:
 
A.
BioZone Phamlaceutical. Inc .. a Delaware corporation having a principal place of business at 580 Garcia Avenue. Pittsburg. CA 94565 ("BPI") is the successor in interest to BioZone Laboratories. Inc. ("BU") and the assignee of the BLI’s entire interest under the Agreement:
 
B.
BetaZone Laboratories LLC ("BetaZone") has developed the ophthalmic products listed in the attached schedule ("Existing Ophthalmic Products") pursuant to the Agreement: and
 
C.
BLI wishes to enter into a new separate license agreement relating to ophthalmic products with a third party;
 
Therefore. BPI and BetaZone agree as follows.
 
1.
BetaZone shall have the right to continue to market and sell Existing Ophthalmic Products pursuant to the Agreement. Such right shall include all other rights necessary to implement such marketing and sales activity. including the right to continue manufacture of Existing Ophthalmic Products pursuant to the Agreement.
 
2.
BetaZone shall not develop. market or sell any new therapeutic and/or preventative ophthalmic products incorporating the confidential information and/or Know-How as defined in the Agreement.
 

 
Signed:
    
/s/ Camillo Rey
  
/s/ Brian Keller
Managing Director
  
CEO
BetaZone
  
BPI
     
04/04/2011
    
Date
  
Date
     

 

 
 

Cocrystal Pharma, Inc. Reports

Also read